AgomAb Therapeutics NV (NASDAQ:AGMB) Short Interest Update

AgomAb Therapeutics NV (NASDAQ:AGMB) saw a significant growth in short interest in April. As of April 30th, there was short interest totaling 755,022 shares, a growth of 74.3% from the April 15th total of 433,265 shares. Based on an average daily volume of 172,021 shares, the days-to-cover ratio is currently 4.4 days. Currently, 2.1% of the company’s stock are sold short.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a research report on Wednesday, March 4th. JPMorgan Chase & Co. assumed coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price objective for the company. Morgan Stanley assumed coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price objective for the company. Wall Street Zen raised AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Finally, Leerink Partners assumed coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 price objective for the company. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, AgomAb Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $32.00.

AgomAb Therapeutics Trading Down 1.3%

Shares of NASDAQ AGMB traded down $0.14 during trading on Monday, reaching $10.41. The company had a trading volume of 1,204 shares, compared to its average volume of 160,238. AgomAb Therapeutics has a 12-month low of $9.00 and a 12-month high of $17.45. The business’s 50-day moving average is $11.74.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.